Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Olivia Lui's Application for the Canada Graduate Scholarships-Master's Program
FY 2019-20
Summary
Characterizing the Impact of Amylase Inhibitors on the Gut Microbiota
The human gut microbiota, a community of over a trillion microbes, is an integral part of our physiology and is important for our health. Many drugs have been shown to have an undesired impact on the gut microbiota with potentially harmful effects on the host. Acarbose, used in the treatment of type II diabetes, prevents the digestion of dietary starches by inhibiting human amylase enzymes to limit blood sugar increase. It can also inhibit the enzymes of certain gut bacteria, inhibiting their ability to take up these starches. In contrast, a diabetes drug in development, montbretin A, has been reported to be selective for the human enzymes, potentially minimizing impact on the gut microbiota. Our objective is to develop an unbiased method to evaluate the effect of amylase inhibitors on gut bacteria, and to follow-up on the enzymes involved. To do so, we will use fluorescent sugar that can be degraded by gut bacteria enzymes and internalized into cells to produce a fluorescent cell and we will measure the level of fluorescence. This process, to be done on human stool samples, is inhibited by acarbose. This method will be used to evaluate the level of sugar uptake of gut bacteria incubated with montbretin A. To follow-up, we will sort fluorescent cells from non-fluorescent cells and sequence their DNA to identify the bacteria and the type of system used for starch metabolism. We hypothesize that montbretin A does not affect bacterial amylases, allowing for starch metabolism by gut bacteria. Understanding the effect on gut microbiota metabolism will improve the design of drugs for diabetes and have a more recent explorative use in cancer immunotherapy.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
436886
Name
Lui Olivia
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Olivia Lui's Application for the Canada Graduate Scholarships-Master's Program
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acarbose; Amylase Inhibitor; Carbohydrate-Active Enzymes; Diabetes Drugs; Gut Microbiota; Metabolic Labelling; Montbretin A; Starch Metabolism
Abstract
Characterizing the Impact of Amylase Inhibitors on the Gut Microbiota
The human gut microbiota, a community of over a trillion microbes, is an integral part of our physiology and is important for our health. Many drugs have been shown to have an undesired impact on the gut microbiota with potentially harmful effects on the host. Acarbose, used in the treatment of type II diabetes, prevents the digestion of dietary starches by inhibiting human amylase enzymes to limit blood sugar increase. It can also inhibit the enzymes of certain gut bacteria, inhibiting their ability to take up these starches. In contrast, a diabetes drug in development, montbretin A, has been reported to be selective for the human enzymes, potentially minimizing impact on the gut microbiota. Our objective is to develop an unbiased method to evaluate the effect of amylase inhibitors on gut bacteria, and to follow-up on the enzymes involved. To do so, we will use fluorescent sugar that can be degraded by gut bacteria enzymes and internalized into cells to produce a fluorescent cell and we will measure the level of fluorescence. This process, to be done on human stool samples, is inhibited by acarbose. This method will be used to evaluate the level of sugar uptake of gut bacteria incubated with montbretin A. To follow-up, we will sort fluorescent cells from non-fluorescent cells and sequence their DNA to identify the bacteria and the type of system used for starch metabolism. We hypothesize that montbretin A does not affect bacterial amylases, allowing for starch metabolism by gut bacteria. Understanding the effect on gut microbiota metabolism will improve the design of drugs for diabetes and have a more recent explorative use in cancer immunotherapy.
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lui, Olivia
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~